Cobenfy, the main asset acquired through Bristol Myers’ $14 billion purchase of Karuna, had $10 million in sales in the ...

Bristol Myers Squibb clocked $10 million in sales for new schizophrenia drug Cobenfy in the fourth quarter of 2024, with the ...

Bristol-Myers Squibb's Cobenfy launch shows strong initial sales and growth potential. Learn why BMY stock is a solid ...

Bristol-Myers Squibb beat Q4 earnings expectations, but the stock fell due to lowered 2025 revenue guidance and patent ...

Cobenfy comes as a capsule. It received Food and Drug Administration approval on Sept. 26 as a treatment for schizophrenia, then launched onto the U.S. market in late October. By Bristol Myers ...

Bristol Myers Squibb will make even deeper cuts to its organization to enhance efficiencies as it faces the 2028 loss of ...

We recently published a list of Jim Cramer Tells Viewers To Not Trust Billionaires & Discusses These 11 Stocks.

We recently published a list of Jim Cramer Discusses These 11 Stocks & President Trump’s Sovereign Wealth Fund.

CBD has shown promise as a treatment for psychosis in small studies and case reports. A large, international trial launching in April aims to put those findings to the test.

Bristol Myers Squibb Co. forecast 2025 sales and profit below Wall Street’s expectations — a sign that declining sales of ...

(Reuters) -Bristol Myers Squibb on Thursday posted better-than-expected fourth-quarter earnings, but said its 2025 revenue ...

It also expressed optimism about Cobenfy’s Alzheimer’s psychosis trials, assigning a 70% probability of success for a key Phase 3 study, and pointed to the drug’s potential efficacy in ...